Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The biotech company got good news about its COVID-19 vaccine.

Why Novavax Stock Jumped on Tuesday

Novavax Inc. NVAX, +1.20% said Tuesday that its COVID-19 vaccine received authorization in Australia and Japan for teens. Both authorizations are for adolescents between the ages of 12 and 17 years old.

Novavax's COVID-19 vaccine is authorized for teens in Australia and Japan

Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md. , July 26, 2022  /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for primary immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md. , July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the Australian Therapeutic Goods Agency (TGA) has granted expanded approval for provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

Novavax offers several clear advantages over its larger rival.

3 Reasons Why Novavax Is a Better Stock to Buy Than Moderna

OrthoPediatrics

 Pliant Therapeutics

Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.

2022 Roundtable: Our Favorite Picks Right Now

The market has lost interest in the race for COVID-19 vaccines, perhaps understandably so.

Why Novavax Stock Is Down More Than 7% Today

Is Novavax stock a buy or a sell after the FDA authorized its Covid shot? Is NVAX stock a buy or a sell right now?

Novavax Wins FDA OK For Covid Shot, But Collapses — Is It A Buy Or A Sell?

Two years after the onset of COVID-19 in the U.S., a new vaccine is coming to market -- who will it help?

Is This Vaccine Stock a Buy After Big News?

Faraday Future Intelligent Electric

Palantir Technologies

Snap

Virgin Galactic

GEO Group

All meme stocks may not be sound investment options. A close scrutiny of these stocks can help to zero in on investment-worthy candidates from among these stocks.

7 Surprising Meme Stocks to Buy and Hold in 2022

The CDC's director signed off late Tuesday, making Novavax available to adults who haven't been vaccinated yet.

CDC Recommends Novavax, the 4th COVID Vaccine to Be Authorized

Novavax stock is up 6% today after the U.S. Centers for Disease Control and Prevention (CDC) approved its two-dose Covid-19 vaccine for use in adults. The post The CDC Just Gave Novavax (NVAX) Stock a Big Boost appeared first on InvestorPlace.

The CDC Just Gave Novavax (NVAX) Stock a Big Boost

Its vaccine might be more effective as a booster than the other options.

Here's How Novavax Stock Could Rally Through 2023

The Centers for Disease Control and Prevention endorsed a committee's recommendation that the Novavax COVID-19 vaccine be used as a primary series option for adults.

Novavax COVID-19 vaccine for adults endorsed by CDC

Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.

Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults

There is good news for the company, but there is more work to do ahead.

Novavax's Shareholders Can Breathe a Sigh of Relief

The U.S. Centers for Disease Control and Prevention authorized the Novavax vaccine for adults late Tuesday, clearing the final obstacle to the use of a fourth alternative and one that is based on more traditional technology than earlier shots.

CDC OK's Novavax vaccine to add fifth shot to U.S. program, and COVID cases triple in Europe in six-week span

They're not easy tasks. But Novavax could potentially achieve them.

2 Things Novavax Must Do to Be a Monster Comeback Stock

The Covid-19 vaccine from Novavax is the fourth approved for use in the United States.

Novavax Stock Surges After CDC Endorses Its Covid-19 Shot

U.S. adults who haven't gotten any COVID-19 shots yet should consider a new option from Novavax — a more traditional kind of vaccine, health officials said Tuesday.

CDC gives final approval for more traditional Novavax COVID vaccine for adults

The CDC's director is expected to accept the recommendation, which will make Novavax available to adults who haven't been vaccinated yet.

CDC Panel Endorses Novavax, a New COVID Vaccine

Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series FDA has determined that first vaccine lot has met all release specifications and is acceptable for use under Emergency Use Authorization Novavax expects to ship doses to the U.S. Government-designated distribution center in the coming days Novavax' vaccine is the first FDA-authorized and ACIP-recommended protein-based COVID-19 vaccine in the U.S. GAITHERSBURG, Md. , July 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend the use of the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series in individuals aged 18 and older.

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older

Shares of Novavax Inc. NVAX, +14.32% jumped 11.9% in trading on Tuesday after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of the company's COVID-19 vaccine. The next step is for CDC director Rochelle Walensky to decide whether to sign off on the decision; if she does, the vaccine will then be made available to adults in the U.S. The Food and Drug Administration granted emergency authorization to the two-dose, protein vaccine last week.

CDC committee recommends Novavax's COVID-19 vaccine

The recommendation from the CDC's Advisory Committee on Immunization Practices heads to CDC director Rochelle Walensky for approval.

CDC Advisors Recommend Novavax Covid Vaccine For Adults

Novavax has several catalysts igniting NVAX stock higher today. The bulls hope this is just the beginning for NVAX shares.

News for Novavax Stock (NVAX)